Retinal pigment epithelium tears following intravitreal ranibizumab therapy.
Two patients with choroidal neovascularization secondary to age-related macular degeneration (AMD) developed a retinal pigment epithelial (RPE) tear following intravitreal injection of ranibizumab. One patient developed the RPE tear within 2 weeks of the injection, the other within 6 weeks of a second injection. Both patients presented with vision loss of one line at diagnosis of the RPE tear. During long-term follow-up, visual acuity improved in one patient by one line and deteriorated in the second patient by three lines. RPE tears may occur after intravitreal injection of ranibizumab in patients with neovascular AMD, probably because of the rapid regression of the fibrovascular membrane.
Kiss
Christopher
C
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Michels
Stephan
S
Prager
Franz
F
Geitzenauer
Wolfgang
W
Schmidt-Erfurth
Ursula
U
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy; D010857:Pigment Epithelium of Eye / Q000187:drug effects*; D000069579:Ranibizumab; D012167:Retinal Perforations / Q000139:chemically induced* / Q000150:complications / Q000175:diagnosis; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000209:etiology / Q000503:physiopathology; D014822:Vitreous Body
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab